MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
Last trade$8.46
Day change-$0.28 (-3.20%)
Day range$8.27 – $8.94
Volume475,541
Market cap$854M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$854.16M
Price / earnings
10.81×
Price / book
3.96×
Price / sales
2.15×
EV / sales
2.09×
EV / EBITDA
4.24×
Profitability
Earnings per share
$0.81
Return on assets
19.92%
Return on equity
36.64%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.56×
Current ratio
3.76×
Quick ratio
3.76×
Cash ratio
2.46×
Cash flow
Price / cash flow
62.4×
Price / free cash flow
81.61×
Free cash flow
$10.47M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MGTX, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$321.43M
$293K
$75.36M
$410K
$3.69M
$1.93M
$21.39M
$10.91M
Cost of revenue
$7.16M
$0
$0
$0
$2.68M
$0
$0
$0
Gross profit
$314.27M
$293K
$75.36M
$410K
$1.02M
$1.93M
$21.39M
$10.91M
Selling, general and administrative
$12.01M
$9.13M
$18.08M
$13.93M
$12.31M
$10.74M
$28.9M
$24.71M
Research and development
$57.83M
$31.98M
$30.81M
$32.53M
$33.5M
$32.78M
$23.99M
$26.24M
Total operating expenses
$69.85M
$41.11M
$48.89M
$46.46M
$45.81M
$43.52M
$52.88M
$50.95M
Operating income
$244.43M
-$40.82M
$26.47M
-$46.05M
-$44.79M
-$41.6M
-$31.49M
-$40.04M
Interest expense
-$3.51M
-$2.85M
-$3.06M
-$3.07M
-$3.03M
-$3.04M
-$3.41M
-$3.36M
Income before taxes
$163.03M
-$46.31M
$15.09M
-$50.51M
-$38.8M
-$39.98M
-$39.4M
-$39.33M
Income taxes
$2.36M
$0
$0
$0
$0
$0
$0
$0
Net income
$160.67M
-$46.31M
$15.09M
-$50.51M
-$38.8M
-$39.98M
-$39.4M
-$39.33M
Net income attributable to common shareholders
$160.72M
-$46.31M
$15.09M
-$50.51M
-$38.8M
-$39.98M
-$39.4M
-$39.33M
EBITDA
$247.25M
-$37.81M
$29.59M
-$42.9M
-$41.6M
-$38.52M
-$28.42M
-$36.78M
Basic earnings per share
$1.76
-$0.57
$0.19
-$0.62
-$0.48
-$0.51
-$0.50
-$0.55
Diluted earnings per share
$1.71
-$0.57
$0.19
-$0.62
-$0.48
-$0.51
-$0.50
-$0.55
Recent news
Company coverage with links to the original publishers.
MeiraGTx announced an oral presentation of its AAV-BDNF gene therapy program at ObesityWeek 2026, showcasing preclinical data demonstrating that a single hypothalamic injection provided durable metabolic and neurobehavioral improvements in BDNF haploinsufficiency models, with favorable safety profiles and sustained weight stabilization over 14 months.
Alpha Cognition Inc. (ACOG) reported a quarterly loss of $0.28 per share, beating the consensus estimate of $0.33 loss, with a 15.15% earnings surprise. The company posted revenues of $7.78 million, surpassing estimates by 9.04% and nearly tripling year-ago revenues of $2.84 million. The stock has gained 34.3% year-to-date, outperforming the S&P 500's 9.9% gain. However, the company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
MeiraGTx Chief Scientific Officer Stuart Naylor sold 27,659 shares (4% of holdings) for $409,000 on July 7, 2026, under a pre-scheduled Rule 10b5-1 trading plan adopted in December 2025. The sale appears routine following an 89% one-year stock surge and likely reflects portfolio diversification rather than lack of confidence. The company remains well-positioned with a Lilly collaboration worth $75M upfront plus $400M+ in milestones, FDA Breakthrough Therapy Designation for its dry-mouth therapy, and plans to file for approval on two wholly-owned therapies within two years.
MeiraGTx reacquired bota-vec, a treatment for X-linked retinitis pigmentosa (XLRP), from Johnson & Johnson for a $25 million upfront payment. The company raised $100 million through a share offering and plans to expedite regulatory filings for U.S. and EU approval with a potential 2027 launch. Three-year data from its xerostomia treatment showed durable benefits. Stock declined 15.8% on the announcement.
MeiraGTx has entered into an asset purchase agreement with Johnson & Johnson to acquire all interests in botaretigene sparoparvovec (bota-vec) for treating X-linked retinitis pigmentosa. The company will pay $25 million upfront plus regulatory and commercial milestones, with royalties on global net sales. Phase 3 LUMEOS study data showed clinically meaningful improvements across multiple vision domains, with 45% of treated patients gaining >10 letters in low luminance visual acuity. MeiraGTx intends to file for regulatory approval in the U.S., EU, and Japan with a potential launch in 2027.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.